Allurion shares rise 14.11% intraday as FDA approval catalyzes compliance plan amid NYSE delisting appeal.

Allurion Technologies (ALUR) surged 14.11% intraday after announcing plans to appeal the NYSE delisting notice and highlighting recent FDA approval as a catalyst for regaining compliance. The company disclosed it failed to meet NYSE’s $50 million equity/market cap requirement but emphasized its FDA approval on February 20, 2026, as a key step toward relisting efforts. Investors likely reacted to the firm’s proactive strategy—including debt restructuring, capital-raising initiatives, and appeals—viewing these measures as confidence-building actions to retain NYSE listing and address liquidity concerns. The FDA approval, targeting obesity treatment for 80 million Americans, further signaled potential for revenue growth and market recovery, aligning with the stock’s sharp intraday rally.